CareDx stock price target lowered to $22 at BTIG on Medicare reimbursement concerns

BTIG reduced its price target on CareDx (NASDAQ:CDNA) to $22 from $26, while maintaining a Buy rating, citing potential $15-30 million annual revenue impact from proposed Medicare reimbursement limitations. Despite the stock's 50% decline over six months and a recent Q2 revenue miss, CareDx reported a positive EPS, maintained its full-year revenue guidance midpoint of $370 million, and demonstrated strong 13% Q2 testing volume growth. BTIG emphasizes the company's positive fundamentals and notes the stock trades at a significant discount to its historical valuation, suggesting undervaluation despite the regulatory headwinds.

Analysis

BTIG has revised its price target for CareDx (CDNA) down to $22.00 from $26.00, primarily due to a proposed Medicare reimbursement change (Palmetto MolDx draft LCD) that could create a $15-30 million annual revenue headwind. Despite this regulatory risk and a recent 50% decline in the stock price, the firm maintained its Buy rating. This decision is contextualized by CareDx's mixed but resilient Q2 2025 performance, where it significantly beat earnings expectations with a $0.10 EPS against a forecasted $0.10 loss, even while missing revenue targets by 4.33% ($86.7 million reported vs. $90.62 million anticipated). The company's underlying fundamentals appear robust, evidenced by a 13% year-over-year growth in testing volumes in Q2, led by a nearly 20% increase in its kidney testing segment. Furthermore, CareDx has maintained the midpoint of its full-year guidance, projecting $370 million in revenue, and possesses a strong balance sheet with a current ratio of 3.3x. The core of the bull thesis rests on valuation; the stock currently trades at 1.2 times BTIG's 2026 revenue estimate, a steep discount compared to its historical average range of 3-7 times revenue, suggesting it is significantly undervalued relative to its operational performance and growth outlook.

Key Decisions for Investors

• Investors should closely monitor any updates on the Palmetto MolDx draft Local Coverage Determination, as its final terms represent the most significant near-term risk to the company's revenue stream.
• Given the stock's 50% price decline and its current valuation at a substantial discount to historical multiples, investors with a higher risk tolerance could view the current level as an attractive entry point, betting that the company's fundamental strength will overcome regulatory pressures.
• Pay close attention to core operational metrics, particularly testing volume growth, as continued momentum in this area is a key indicator of underlying demand and the company's ability to absorb potential reimbursement cuts.
• The significant Q2 EPS beat, despite a revenue miss, suggests strong cost management and operational efficiency, which should be considered a positive sign of management's ability to navigate a challenging environment.